Literature DB >> 9219238

Anti-HIV ribozymes.

L Q Sun1, J A Ely, W Gerlach, G Symonds.   

Abstract

HIV is an RNA virus that replicates intracellularly through various RNA intermediates. Several of these can be targeted by ribozymes (catalytic RNA molecules), and a number of investigators, including this group, have demonstrated the ability of ribozymes to suppress HIV replication in this way. It is argued that this gene therapy approach may be viewed as an adjunct to chemotherapeutic drugs, which may allow not just viral suppression, but also immune restoration. This can only finally be tested in clinical trials, and several are planned. The basic ribozyme unit, the potential of which was described less than 10 years ago, is about to be tested in an amunable disease state.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219238     DOI: 10.1007/BF02740815

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  74 in total

1.  Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector.

Authors:  S Chatterjee; P R Johnson; K K Wong
Journal:  Science       Date:  1992-11-27       Impact factor: 47.728

2.  Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.

Authors:  C J Chen; A C Banerjea; G G Harmison; K Haglund; M Schubert
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

Review 3.  Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.

Authors:  J J Rossi; D Elkins; J A Zaia; S Sullivan
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

4.  HIV and other lentivirus-based vectors.

Authors:  A M Lever
Journal:  Gene Ther       Date:  1996-06       Impact factor: 5.250

5.  A small catalytic oligoribonucleotide.

Authors:  O C Uhlenbeck
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

Review 6.  HIV accessory proteins: leading roles for the supporting cast.

Authors:  D Trono
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

7.  Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.

Authors:  M Homann; S Tzortzakaki; K Rittner; G Sczakiel; M Tabler
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

8.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.

Authors:  J C Burns; T Friedmann; W Driever; M Burrascano; J K Yee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

9.  Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1.

Authors:  O Heidenreich; F Eckstein
Journal:  J Biol Chem       Date:  1992-01-25       Impact factor: 5.157

10.  Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro.

Authors:  J P Maciejewski; F F Weichold; N S Young; A Cara; D Zella; M S Reitz; R C Gallo
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

View more
  4 in total

1.  Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P.

Authors:  D Plehn-Dujowich; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

2.  Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model.

Authors:  M Andäng; J Hinkula; G Hotchkiss; S Larsson; S Britton; F Wong-Staal; B Wahren; L Ahrlund-Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:  Ronald T Mitsuyasu; Thomas C Merigan; Andrew Carr; Jerome A Zack; Mark A Winters; Cassy Workman; Mark Bloch; Jacob Lalezari; Stephen Becker; Lorna Thornton; Bisher Akil; Homayoon Khanlou; Robert Finlayson; Robert McFarlane; Don E Smith; Roger Garsia; David Ma; Matthew Law; John M Murray; Christof von Kalle; Julie A Ely; Sharon M Patino; Alison E Knop; Philip Wong; Alison V Todd; Margaret Haughton; Caroline Fuery; Janet L Macpherson; Geoff P Symonds; Louise A Evans; Susan M Pond; David A Cooper
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

4.  Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt.

Authors:  Ronald T Mitsuyasu; Jerome A Zack; Janet L Macpherson; Geoff P Symonds
Journal:  Stem Cells Int       Date:  2011-06-13       Impact factor: 5.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.